Bevacizumab: A dose review

被引：34

作者：

Falk, Alexander T. ^{[1
]}

Barriere, Jerome ^{[1
]}

Francois, Eric ^{[1
]}

Follana, Philippe ^{[1
]}

机构：

[1] Ctr Antoine Lacassagne, F-06000 Nice, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 03期

关键词：

Bevacizumab; Dose; In vitro; In vivo; Clinical outcomes; ENDOTHELIAL GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER; PHASE-II TRIAL; RECURRENT EPITHELIAL OVARIAN; ORAL CYCLOPHOSPHAMIDE; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; PRIMARY PERITONEAL; TUMOR PROGRESSION; RANDOMIZED-TRIAL;

D O I：

10.1016/j.critrevonc.2015.01.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is a key process in cancer development and has been described has a hallmark of cancer. Two dose-intensities were approved for cancer treatment by the Food and Drug Administration and European Medicines Agency: 2.5 mg/kg/week dose equivalent and 5 mg/kg/week dose equivalent. While bevacizumab has shown its effectiveness in clinical trials, pharmacodynamics is not fully understood and a dose-effect relationship has not been proven in vivo. Direct trials comparing high or low doses are rare with potential dose-effect toxicity. Discordant data have been reported on the efficacy of doses. This review discusses the dose of bevacizumab via the analysis of studies that led to the approval of bevacizumab in clinical practice. Optimization of doses schemes could reduce potential dose-effect toxicities, potentiate synergetic effects with chemotherapy and permit the prescription to a larger population with a better cost-effectiveness ratio. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：311 / 322

页数：12

共 72 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].